MSA
SAGE

Marino Stram & Associates’s Sage Therapeutics SAGE Stock Holding History

Marino Stram & Associates’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10
Closed -$2K – 463
2019
Q1 		$2K Hold
10
– – ﹤0.01% 547
2018
Q4 		$1K Buy
+10
New +$1.14K ﹤0.01% 580

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Marino Stram & Associates's SAGE Position: Q2 2019 in Review

Marino Stram & Associates sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 10 shares — an estimated $2K sold.

Marino Stram & Associates first reported a position in SAGE in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

  • Marino Stram & Associates reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Marino Stram & Associates sold 10 Sage Therapeutics shares in Q2 2019, an estimated $2K.
  • Marino Stram & Associates first reported a position in Sage Therapeutics in Q4 2018 and held it in 2 quarters.
  • Marino Stram & Associates's Sage Therapeutics position peaked at $2K in Q1 2019.
  • 272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on Marino Stram & Associates's 13F filing for Q2 2019, filed 19 Jul 2019.